Generic Name	Any Pharmacology Description	Any Indication	Any Indication Status
bevacizumab	Endothelial growth factor antagonist Angiogenesis inhibitor	Cancer, colorectal Cancer, lung, non-small cell Cancer, breast Cancer, renal Cancer, pancreatic Cancer, prostate Cancer, ovarian Cancer, brain Cancer, lung, small cell	Launched Launched Pre-registration Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase II Clinical Trial Preclinical
bosentan	Endothelin A receptor antagonist Endothelin B receptor antagonist	Hypertension, pulmonary Heart failure Fibrosis, pulmonary Ulcer, general Scleroderma Anaemia, sickle cell Cancer, melanoma Haemorrhage, subarachnoid	Launched Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase II Clinical Trial Phase I Clinical Trial
efalizumab	CD11a antagonist T cell inhibitor	Psoriasis Transplant rejection, general Arthritis, psoriatic Eczema, atopic	Launched Phase II Clinical Trial Phase II Clinical Trial Phase I Clinical Trial
interferon, Genentech (gamma1b)	Interferon gamma 1b agonist	Chronic granulomatous disease Osteopetrosis Infection, tuberculosis Infection, respiratory tract, general Eczema, atopic Fibrosis, pulmonary Fibrosis, liver Cystic fibrosis Infection, meningitis, general Asthma Wound healing	Launched Launched Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase II Clinical Trial Phase II Clinical Trial Phase II Clinical Trial Phase II Clinical Trial
rituximab	CD20 antagonist Complement factor stimulant	Cancer, lymphoma, non-Hodgkin`s Cancer, lymphoma, B-cell Arthritis, rheumatoid Cancer, leukaemia, chronic lymphocytic Multiple sclerosis, chronic progressive Lupus erythematosus, systemic Lupus nephritis Multiple sclerosis, relapsing-remitting Colitis, ulcerative	Launched Launched Launched Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase III Clinical Trial Phase II Clinical Trial Phase II Clinical Trial
trastuzumab	ErbB-2 inhibitor	Cancer, breast Cancer, gastrointestinal, general Cancer, lung, non-small cell	Launched Phase III Clinical Trial Phase II Clinical Trial
Examples of Genentech's Launched Drugs Being Developed for Additional Indications